Header Logo

Connection

Patrick Arbuthnot to Animals

Back to Details
This is a "connection" page, showing publications Patrick Arbuthnot has written about Animals.
Patrick Arbuthnot
Connection Strength
2,982
Animals
  1. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
    View in: PubMed
    Score: 0,140
  2. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019 Sep 12; 19(1):802.
    View in: PubMed
    Score: 0,132
  3. Gene and cell therapy in South Africa: Current status and future prospects. S Afr Med J. 2019 Sep 10; 109(8b):12-16.
    View in: PubMed
    Score: 0,132
  4. Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 2016 12; 16(12):1517-1527.
    View in: PubMed
    Score: 0,107
  5. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016 Apr; 24(4):671-7.
    View in: PubMed
    Score: 0,103
  6. Hepatic Delivery of Artificial Micro RNAs Using Helper-Dependent Adenoviral Vectors. Methods Mol Biol. 2016; 1364:249-60.
    View in: PubMed
    Score: 0,102
  7. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
    View in: PubMed
    Score: 0,100
  8. The role of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Virus Res. 2016 Jan 02; 212:103-13.
    View in: PubMed
    Score: 0,099
  9. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. J Control Release. 2015 Jul 10; 209:198-206.
    View in: PubMed
    Score: 0,097
  10. Recent advances in use of gene therapy to treat hepatitis B virus infection. Adv Exp Med Biol. 2015; 848:31-49.
    View in: PubMed
    Score: 0,095
  11. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
    View in: PubMed
    Score: 0,094
  12. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
    View in: PubMed
    Score: 0,092
  13. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther. 2014; 19(4):363-73.
    View in: PubMed
    Score: 0,088
  14. Recent advances in developing nucleic acid-based HBV therapy. Future Microbiol. 2013 Nov; 8(11):1489-504.
    View in: PubMed
    Score: 0,088
  15. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.
    View in: PubMed
    Score: 0,086
  16. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. Bioorg Med Chem. 2013 Oct 15; 21(20):6145-55.
    View in: PubMed
    Score: 0,085
  17. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. Microrna. 2012; 1(1):19-25.
    View in: PubMed
    Score: 0,077
  18. Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev Med Virol. 2011 Nov; 21(6):383-96.
    View in: PubMed
    Score: 0,076
  19. MicroRNA-like antivirals. Biochim Biophys Acta. 2011 Nov-Dec; 1809(11-12):746-55.
    View in: PubMed
    Score: 0,074
  20. tRNA Lys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. Biochem Biophys Res Commun. 2010 Aug 06; 398(4):640-6.
    View in: PubMed
    Score: 0,070
  21. Harnessing RNA interference for the treatment of viral infections. Drug News Perspect. 2010 Jul-Aug; 23(6):341-50.
    View in: PubMed
    Score: 0,070
  22. Efficient nucleic acid transduction with lipoplexes containing novel piperazine- and polyamine-conjugated cholesterol derivatives. Bioorg Med Chem Lett. 2009 Jan 01; 19(1):100-3.
    View in: PubMed
    Score: 0,062
  23. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther. 2008 Nov; 19(11):1325-31.
    View in: PubMed
    Score: 0,062
  24. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther. 2008 Jun; 16(6):1105-12.
    View in: PubMed
    Score: 0,060
  25. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J Gastroenterol. 2008 Mar 21; 14(11):1670-81.
    View in: PubMed
    Score: 0,060
  26. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat. 2007 Jul; 14(7):447-59.
    View in: PubMed
    Score: 0,057
  27. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther. 2007 Mar; 15(3):534-41.
    View in: PubMed
    Score: 0,055
  28. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb; 13(2):411-21.
    View in: PubMed
    Score: 0,051
  29. Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector. Virol J. 2025 Feb 17; 22(1):41.
    View in: PubMed
    Score: 0,048
  30. Diversity of Dysregulated Long Non-Coding RNAs in HBV-Related Hepatocellular Carcinoma. Front Immunol. 2022; 13:834650.
    View in: PubMed
    Score: 0,039
  31. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virol J. 2021 12 13; 18(1):247.
    View in: PubMed
    Score: 0,039
  32. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,038
  33. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
    View in: PubMed
    Score: 0,037
  34. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol. 2001 Apr; 82(2):77-100.
    View in: PubMed
    Score: 0,037
  35. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol. 2000 Apr; 15(4):357-68.
    View in: PubMed
    Score: 0,034
  36. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods Mol Biol. 2020; 2115:171-183.
    View in: PubMed
    Score: 0,034
  37. Simplified ELISA for detecting antibodies to recombinant fusion proteins. Biotechniques. 1997 Oct; 23(4):627-30.
    View in: PubMed
    Score: 0,029
  38. Longitudinal in vivo bioimaging of hepatocyte transcription factor activity following cholestatic liver injury in mice. Sci Rep. 2017 02 03; 7:41874.
    View in: PubMed
    Score: 0,028
  39. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther. 1996 Aug 20; 7(13):1503-14.
    View in: PubMed
    Score: 0,027
  40. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology. 1995 Dec; 22(6):1788-96.
    View in: PubMed
    Score: 0,025
  41. In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters. Sci Rep. 2015 Jul 03; 5:11842.
    View in: PubMed
    Score: 0,025
  42. Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7(12):e51952.
    View in: PubMed
    Score: 0,021
  43. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2010 Apr 19; 143(2):222-32.
    View in: PubMed
    Score: 0,017
  44. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm. 2009 May-Jun; 6(3):706-17.
    View in: PubMed
    Score: 0,016
  45. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology. 2007 Jun; 45(6):1390-9.
    View in: PubMed
    Score: 0,014
  46. Purine nucleoside and nucleotide regulation of high affinity [3H]glutamate and [3H]aspartate uptake into rat brain synaptosomes. Int J Biochem. 1985; 17(6):753-5.
    View in: PubMed
    Score: 0,012
  47. Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog. 2004 May; 40(1):34-46.
    View in: PubMed
    Score: 0,011
  48. Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia. 2003 May-Jun; 5(3):229-44.
    View in: PubMed
    Score: 0,011
  49. Hepatitis Bx antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia. 2002 Jul-Aug; 4(4):355-68.
    View in: PubMed
    Score: 0,010
  50. A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival. Hepatology. 2001 Jul; 34(1):146-57.
    View in: PubMed
    Score: 0,009
  51. The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene. 1999 Mar 04; 18(9):1677-87.
    View in: PubMed
    Score: 0,008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.